Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) and Evolent Health (NYSE:EVH – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Profitability
This table compares Firefly Neuroscience and Evolent Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Firefly Neuroscience | -506.23% | -90.17% | -72.05% |
| Evolent Health | -24.08% | -4.27% | -1.06% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Firefly Neuroscience and Evolent Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Firefly Neuroscience | 1 | 0 | 0 | 0 | 1.00 |
| Evolent Health | 1 | 4 | 12 | 0 | 2.65 |
Earnings and Valuation
This table compares Firefly Neuroscience and Evolent Health”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Firefly Neuroscience | $1.14 million | 14.86 | -$19.88 million | ($0.59) | -1.83 |
| Evolent Health | $1.88 billion | 0.29 | -$534.51 million | ($4.57) | -1.04 |
Firefly Neuroscience has higher earnings, but lower revenue than Evolent Health. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Firefly Neuroscience has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Evolent Health has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
Insider & Institutional Ownership
5.0% of Firefly Neuroscience shares are held by institutional investors. 6.9% of Firefly Neuroscience shares are held by company insiders. Comparatively, 1.5% of Evolent Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Evolent Health beats Firefly Neuroscience on 9 of the 14 factors compared between the two stocks.
About Firefly Neuroscience
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
About Evolent Health
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Receive News & Ratings for Firefly Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firefly Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
